Gastroenterology Research and Practice

Gastroenterology Research and Practice / 2018 / Article

Comment on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”

  • Negin Kashani | Amin Talebi Bezmin Abadi |
  •  Article ID 5173904 |
  •  Published 20 Feb 2018

Response to: Comment on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”

  • Soichiro Sue | Nobumi Suzuki | ... | Shin Maeda |
  •  Article ID 8046838 |
  •  Published 22 Mar 2018
  • | View Article

Comment #2 on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”

  • Davide Giuseppe Ribaldone | Marco Astegiano |
  •  Article ID 5260358 |
  •  Published 16 Dec 2018
  • | View Article

Letter to the Editor | Open Access

Volume 2018 |Article ID 5173904 | 3 pages | https://doi.org/10.1155/2018/5173904

Comment on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”

Academic Editor: Tatsuya Toyokawa
Received25 Oct 2017
Accepted13 Dec 2017
Published20 Feb 2018

We read with great interest the prospective study by Sue et al. evaluating a 7-day therapy against H. pylori using VPZ/CAM/MNZ (VCM) in twenty patients with allergy to penicillin [1]. This survey showed that the effectiveness of VPZ-based regimen is much more than PPI-based therapy applied to those 29 Japanese patients (95% CI: 86.1–100%). At least in Japan, vonoprazan is bringing a novel era in the management of gastric acid-related diseases [2]. Although the study by Sue et al. was a novel prospective trial, there are some ethical and technical issues in light of population limitations which may influence the final conclusion by the authors.

1. Generalization of the Finding

The main limitation of this survey is the lack of blinding of the study design. This problem directly reduces the ability of generalization for Japanese patients. As an internal control, they should have used a crossover modification in their design for subjects. This item is highly suggested for similar studies in the future. On the other hand, vonoprazan application is restricted to Japan and there is no clue what would happen if it is prescribed by American, Iranian, or Indian gastroenterologists for H. pylori-infected patients! This is the main challenge in treating subjects worldwide.

2. Factors Affecting the Success of Treatment

Although both the intention-to-treat and per-protocol effectiveness of VPZ-based eradication were found to be 100% (95% CI: 86.1–100%) in this study, the factors affecting the success rate of H. pylori therapy were not checked. For example, the smoking situation and alcohol-drinking habits could be valuable candidates to investigate. The consistency of the current finding (100% eradication rate for therapy) can be reevaluated in the condition of those defined queries in Japanese subjects.

3. Clarithromycin and Metronidazole Resistance

It has been documented that clarithromycin-based triple therapy (1–2 weeks) is a standard for Asian countries [3], but we need to first check local levels of antibiotic resistance. In this study, there is no clue about those necessary data. Broadly defined, anti-H. pylori therapy using clarithromycin is bound to be defeated in the case of high clarithromycin resistance (>20%). In Japan, clarithromycin resistance has quickly increased, and the current resistance rate is 27.7% [4, 5]. The importance of the current point is higher if we address that the authors aimed to recommend this regimen as the first-line therapy against H. pylori infection [1]. Similar to clarithromycin, the story is even worse for metronidazole. The mean range of resistance to metronidazole in Asian countries is more than 55%, a fact which reduces the chance of success in regimens using this futile antibiotic against H. pylori [6]. Sue et al. did not report data on susceptibility profile for their patients. In fact, clinicians need to have this pattern to reduce antibiotic resistance in patients.

4. Population Size

As a prospective study, it is not far from the mind to expect a better sample size at least for the vonoprazan-receiving group (). In Table 1, it is clear that most of the studies in the case of vonoprazan included more subjects than Sue et al. [1]. Additionally, this study was performed at a single medical center which again limits the chance of generalization of the results. Therefore, the statistical power of the study is under question.


TitleYearAuthorsNumber of patients

“Vonoprazan, A Novel Potassium-Competitive Acid Blocker, as a Component of First-Line and Second-Line Triple Therapy for Helicobacter pylori Eradication: A Phase III, Randomised, Double-Blind Study”2016Murakami et al.650
“Randomised Clinical Trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeated Doses of TAK-438 (Vonoprazan), a Novel Potassium-Competitive Acid Blocker, in Healthy Male Subjects”2015Jenkins et al.60
“Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/Non-Japanese Subjects”2015Sakurai et al.84
“Vonoprazan versus Conventional Proton Pump Inhibitor-Based Triple Therapy as First-Line Treatment against Helicobacter pylori: A Multicenter Retrospective Study in Clinical Practice”2016Shichijo et al.2715
“Safety and Sfficacy of Vonoprazan-Based Triple Therapy against Helicobacter pylori Infection: A Single-Center Experience with 1118 Patients”2016Nakao et al.1172
Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance”2016Matsumoto et al.125
“A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-Containing 7-Day Triple Therapy against Helicobacter pylori2016Noda et al.146
“Usefulness of Vonoprazan, a Potassium Ion-Competitive Acid Blocker, for Primary Eradication of Helicobacter pylori2016Yamada et al.2507
“Vonoprazan Improves the Afficacy of Helicobacter pylori Eradication Therapy with a Regimen Consisting of Clarithromycin and Metronidazole in Patients Allergic to Penicillin”2017Ono et al.88

5. Ethical Considerations

Although the authors addressed that this study is not a randomized clinical trial, there are some ethical considerations which are already neglected. The authors performed endoscopy surgery for diagnostic purposes using the antral biopsies in bacterial culture. Interestingly, IgG serum analysis was performed which is enough. Now, the query is about the accuracy of ethical consideration. It is definitely unacceptable to use an invasive method in H. pylori diagnosis while a noninvasive method is conducted at the same time. Taking together, vonoprazan-based triple therapy showed superiority in treating the H. pylori infection in comparison with PPI-based therapy. Meanwhile, we should not forget that an optimal anti-H. pylori therapy is what eradicates the bacterium in all subjects with minimal side effects, cost, and ethical considerations.

Conflicts of Interest

The authors declared that they have no conflicts of interest.

Authors’ Contributions

All authors have contributed equally to this manuscript and approved the final version of the article.

References

  1. S. Sue, N. Suzuki, W. Shibata et al., “First-line helicobacter pylori eradication with vonoprazan, clarithromycin, and metronidazole in patients allergic to penicillin,” Gastroenterology Research and Practice, vol. 2017, Article ID 2019802, 6 pages, 2017. View at: Publisher Site | Google Scholar
  2. K. Ashida, Y. Sakurai, T. Hori et al., “Randomised clinical trial: vonoprazan, a novel potassium- competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis,” Alimentary Pharmacology and Therapeutics, vol. 43, no. 2, pp. 240–251, 2016. View at: Publisher Site | Google Scholar
  3. V. Mahachai, R. K. Vilaichone, R. Pittayanon et al., “H. Pylori management in ASEAN: the Bangkok consensus report,” Journal of Gastroenterology and Hepatology, vol. 33, no. 1, pp. 37–56, 2017. View at: Publisher Site | Google Scholar
  4. I. Kobayashi, K. Murakami, M. Kato et al., “Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005,” Journal of Clinical Microbiology, vol. 45, no. 12, pp. 4006–4010, 2007. View at: Publisher Site | Google Scholar
  5. T. Nishida, M. Tsujii, H. Tanimura et al., “Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan,” World Journal of Gastroenterology, vol. 20, no. 15, pp. 4362–4369, 2014. View at: Publisher Site | Google Scholar
  6. D. Y. Graham and L. Fischbach, “Helicobacter pylori treatment in the era of increasing antibiotic resistance,” Gut, vol. 59, no. 8, pp. 1143–1153, 2010. View at: Publisher Site | Google Scholar

Copyright © 2018 Negin Kashani and Amin Talebi Bezmin Abadi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

910 Views | 284 Downloads | 4 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.